Does the media prefer TGTX or BNTX?

In the previous week, TG Therapeutics had 5 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for TG Therapeutics and 10 mentions for BioNTech. TG Therapeutics' average media sentiment score of 0.62 beat BioNTech's score of 0.59 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, TGTX or INSM?

TG Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 9.10 $447.18M $2.86 12.81 Insmed $819.56M 27.43 -$1.28B -$5.75 N/A

Is TGTX or INSM more profitable?

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% Insmed -144.44% -130.11% -51.57%

Does the media prefer TGTX or INSM?

In the previous week, Insmed had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 16 mentions for Insmed and 15 mentions for TG Therapeutics. Insmed's average media sentiment score of 1.50 beat TG Therapeutics' score of 0.62 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 14 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer TGTX or ROIV?

In the previous week, TG Therapeutics had 10 more articles in the media than Roivant Sciences. MarketBeat recorded 15 mentions for TG Therapeutics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.28 beat TG Therapeutics' score of 0.62 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VTRS or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Viatris' net margin of -2.04%. TG Therapeutics' return on equity of 88.73% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% TG Therapeutics 65.95% 88.73% 43.44%

Is TGTX or MRNA more profitable?

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -143.55%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% Moderna -143.55% -26.64% -19.32%

Does the media refer more to TGTX or MRNA?

In the previous week, Moderna had 10 more articles in the media than TG Therapeutics. MarketBeat recorded 25 mentions for Moderna and 15 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.62 beat Moderna's score of 0.53 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 9 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive

TG Therapeutics (TGTX) Competitors

$36.64 -0.77 (-2.06%)

Closing price 06/2/2026 04:00 PM Eastern

Extended Trading

$38.40 +1.76 (+4.80%)

As of 08:25 AM Eastern

Compare

TGTX vs. BNTX, INSM, ROIV, VTRS, and MRNA

Should you buy TG Therapeutics stock or one of its competitors? MarketBeat compares TG Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TG Therapeutics include BioNTech (BNTX), Insmed (INSM), Roivant Sciences (ROIV), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does TG Therapeutics compare to BioNTech?

TG Therapeutics (NASDAQ:TGTX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

TG Therapeutics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.10	$447.18M	$2.86	12.81
BioNTech	$3.25B	6.94	-$1.29B	-$5.88	N/A

In the previous week, TG Therapeutics had 5 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for TG Therapeutics and 10 mentions for BioNTech. TG Therapeutics' average media sentiment score of 0.62 beat BioNTech's score of 0.59 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to BioNTech's net margin of -44.39%. TG Therapeutics' return on equity of 88.73% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
BioNTech	-44.39%	-5.30%	-4.62%

TG Therapeutics presently has a consensus target price of $52.50, indicating a potential upside of 43.29%. BioNTech has a consensus target price of $129.56, indicating a potential upside of 45.35%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Summary

TG Therapeutics beats BioNTech on 11 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Insmed?

TG Therapeutics (NASDAQ:TGTX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

TG Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.10	$447.18M	$2.86	12.81
Insmed	$819.56M	27.43	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 16 mentions for Insmed and 15 mentions for TG Therapeutics. Insmed's average media sentiment score of 1.50 beat TG Therapeutics' score of 0.62 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

58.6% of TG Therapeutics shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TG Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Insmed	-144.44%	-130.11%	-51.57%

TG Therapeutics currently has a consensus price target of $52.50, indicating a potential upside of 43.29%. Insmed has a consensus price target of $210.95, indicating a potential upside of 103.37%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

TG Therapeutics beats Insmed on 9 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Roivant Sciences?

TG Therapeutics (NASDAQ:TGTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

TG Therapeutics has a net margin of 65.95% compared to Roivant Sciences' net margin of -3,629.19%. TG Therapeutics' return on equity of 88.73% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

TG Therapeutics presently has a consensus price target of $52.50, indicating a potential upside of 43.29%. Roivant Sciences has a consensus price target of $33.59, indicating a potential upside of 18.91%. Given TG Therapeutics' higher possible upside, equities research analysts clearly believe TG Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.10	$447.18M	$2.86	12.81
Roivant Sciences	$8.26M	2,459.97	-$299.77M	-$0.60	N/A

In the previous week, TG Therapeutics had 10 more articles in the media than Roivant Sciences. MarketBeat recorded 15 mentions for TG Therapeutics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.28 beat TG Therapeutics' score of 0.62 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Summary

TG Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

TG Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A
TG Therapeutics	$616.29M	9.10	$447.18M	$2.86	12.81

Viatris currently has a consensus target price of $16.43, indicating a potential upside of 4.71%. TG Therapeutics has a consensus target price of $52.50, indicating a potential upside of 43.29%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

79.9% of Viatris shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, TG Therapeutics had 14 more articles in the media than Viatris. MarketBeat recorded 15 mentions for TG Therapeutics and 1 mentions for Viatris. Viatris' average media sentiment score of 1.89 beat TG Therapeutics' score of 0.62 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Very Positive
TG Therapeutics	Positive

Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Viatris' net margin of -2.04%. TG Therapeutics' return on equity of 88.73% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
TG Therapeutics	65.95%	88.73%	43.44%

Summary

TG Therapeutics beats Viatris on 13 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Moderna?

TG Therapeutics (NASDAQ:TGTX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Moderna had 10 more articles in the media than TG Therapeutics. MarketBeat recorded 25 mentions for Moderna and 15 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.62 beat Moderna's score of 0.53 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	9 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive

TG Therapeutics presently has a consensus target price of $52.50, indicating a potential upside of 43.29%. Moderna has a consensus target price of $35.73, indicating a potential downside of 21.71%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

TG Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

TG Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.10	$447.18M	$2.86	12.81
Moderna	$1.94B	9.32	-$2.82B	-$8.15	N/A

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -143.55%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Moderna	-143.55%	-26.64%	-19.32%

Summary

TG Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TGTX vs. The Competition

Export

Metric	TG Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.73B	$3.32B	$6.32B	$12.58B
Dividend Yield	N/A	2.33%	2.69%	5.45%
P/E Ratio	12.81	17.44	21.04	24.56
Price / Sales	9.10	322.57	559.52	127.44
Price / Cash	13.35	116.27	42.31	57.88
Price / Book	8.98	6.50	9.93	6.75
Net Income	$447.18M	$24.15M	$3.56B	$337.19M
7 Day Performance	-6.53%	-2.46%	-0.44%	1.88%
1 Month Performance	8.29%	1.16%	4.59%	6.59%
1 Year Performance	0.63%	46.65%	27.59%	35.52%

TG Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TGTX TG Therapeutics	3.9107 of 5 stars	$36.64 -2.1%	$52.50 +43.3%	+2.5%	$5.73B	$616.29M	12.81	290	Analyst Upgrade
BNTX BioNTech	3.6983 of 5 stars	$92.14 flat	$128.44 +39.4%	-21.2%	$23.30B	$3.25B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7815 of 5 stars	$106.24 flat	$210.95 +98.6%	+44.7%	$23.03B	$606.42M	N/A	1,664	Positive News
ROIV Roivant Sciences	3.008 of 5 stars	$29.96 flat	$33.05 +10.3%	+152.9%	$21.44B	$8.26M	N/A	860	Gap Up
VTRS Viatris	3.2085 of 5 stars	$16.65 flat	$16.43 -1.3%	+80.6%	$19.39B	$14.30B	N/A	30,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TGTX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Competitors

TGTX vs. BNTX, INSM, ROIV, VTRS, and MRNA

How does TG Therapeutics compare to BioNTech?

Summary

How does TG Therapeutics compare to Insmed?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Summary

How does TG Therapeutics compare to Viatris?

Summary

How does TG Therapeutics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Competitors

TGTX vs. BNTX, INSM, ROIV, VTRS, and MRNA

How does TG Therapeutics compare to BioNTech?

Which has better earnings and valuation, TGTX or BNTX?

Does the media prefer TGTX or BNTX?

Is TGTX or BNTX more profitable?

Do analysts prefer TGTX or BNTX?

Do institutionals and insiders believe in TGTX or BNTX?

Which has more volatility and risk, TGTX or BNTX?

Summary

How does TG Therapeutics compare to Insmed?

Which has higher earnings and valuation, TGTX or INSM?

Does the media prefer TGTX or INSM?

Do insiders & institutionals have more ownership in TGTX or INSM?

Which has more risk & volatility, TGTX or INSM?

Is TGTX or INSM more profitable?

Do analysts rate TGTX or INSM?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Is TGTX or ROIV more profitable?

Do institutionals & insiders believe in TGTX or ROIV?

Do analysts recommend TGTX or ROIV?

Which has stronger earnings and valuation, TGTX or ROIV?

Does the media prefer TGTX or ROIV?

Which has more volatility & risk, TGTX or ROIV?

Summary

How does TG Therapeutics compare to Viatris?

Which has stronger earnings & valuation, VTRS or TGTX?

Do analysts prefer VTRS or TGTX?

Do insiders and institutionals believe in VTRS or TGTX?

Does the media refer more to VTRS or TGTX?

Which has more risk & volatility, VTRS or TGTX?

Is VTRS or TGTX more profitable?

Summary

How does TG Therapeutics compare to Moderna?

Do institutionals and insiders believe in TGTX or MRNA?

Does the media refer more to TGTX or MRNA?

Do analysts prefer TGTX or MRNA?

Which has more volatility and risk, TGTX or MRNA?

Which has higher earnings and valuation, TGTX or MRNA?

Is TGTX or MRNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools